ZVRA — Zevra Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $253.21m
- $243.49m
- $27.46m
Annual cashflow statement for Zevra Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24.5 | -12.8 | -8.55 | -41.5 | -46 |
| Depreciation | |||||
| Non-Cash Items | 5.6 | 10.2 | 19.1 | 26.1 | 8.86 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -5.12 | 0.374 | -0.357 | -4.25 | 2.65 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -23.7 | -1.94 | 10.4 | -18.7 | -33.5 |
| Capital Expenditures | -0.026 | -0.033 | -0.102 | -0.093 | -0.296 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 3.26 | — | -15.4 | -36.6 | -17.1 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 3.23 | -0.033 | -15.5 | -36.7 | -17.4 |
| Financing Cash Flow Items | -0.3 | -0.118 | 73.9 | -0.033 | 0.692 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.94 | 2.74 | 113 | 8.35 | 28.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -15.6 | 0.767 | 108 | -46.9 | -22.4 |